Dinutuximab is an anti-GD2 monoclonal antibody. Dinutuximab beta was approved for the treatment of patients with high-risk neuroblastoma. In combination with interleukin-2, dinutuximab beta is used to treat those who have not achieved a complete response after first-line therapy.